Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Healthcare Focus Minnesota.
Press releases published on June 12, 2025
Diagonal Therapeutics to Present New Preclinical Data Demonstrating Disease-Modifying Potential of Receptor Clustering Antibody Approach in HHT at EHA 2025 Congress
GlobeNewswire
·
June 12, 2025
Results demonstrate potential of Company’s clustering antibody approach to address key challenges in HHT disease manifestations: restoring ALK1-mediated cellular signaling, preventing and reversing arteriovenous malformations, and preventing HHT-associated …
AB Science announces issuance of a Canadian patent protecting the composition of matter of AB8939, including its use in the treatment of acute myeloid leukemia, with protection until 2036
GlobeNewswire
·
June 12, 2025
PRESS RELEASE AB SCIENCE ANNOUNCES ISSUANCE OF A CANADIAN PATENT PROTECTING THE COMPOSITION OF MATTER OF AB8939, INCLUDING ITS USE IN THE TREATMENT OF ACUTE MYELOID LEUKEMIA (AML), WITH PROTECTION UNTIL 2036 THIS PATENT COMPLETES INTELLECTUAL PROPERTY …
AB Science annonce la délivrance d’un brevet canadien protégeant la composition de matière d’AB8939, y compris son utilisation dans le traitement de la leucémie myéloide aigue, avec une protection jusqu’à 2036
GlobeNewswire
·
June 12, 2025
COMMUNIQUÉ DE PRESSE AB SCIENCE ANNONCE LA DÉLIVRANCE D'UN BREVET CANADIEN PROTÉGEANT LA COMPOSITION DE MATIERE D’AB8939, Y COMPRIS SON UTILISATION DANS LE TRAITEMENT DE LA LEUCÉMIE MYÉLOÏDE AIGUË (LMA), AVEC UNE PROTECTION JUSQU'EN 2036 CE BREVET COMPLÈTE …
Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity
GlobeNewswire
·
June 12, 2025
Dapirolizumab pegol (DZP) showed efficacy across multiple clinical endpoints in the PHOENYCS GO study, including fatigue and measures of disease activity DZP showed consistent improvements in fatigue, a common and debilitating symptom of systemic lupus …
AstriVax Therapeutics Further Strengthens Team with the Appointment of Dieter Weinand as New Chair of the Board of Directors
GlobeNewswire
·
June 12, 2025
US-based Dieter Weinand is the former CEO of Bayer Pharma with more than 25 years of experience as a senior business leader in the pharmaceutical industry The appointment comes as AstriVax Therapeutics matures as a clinical stage immunotherapy company with …
UK leads G7 countries in addressing child sexual violence, but ODA cuts are hurting progress
GlobeNewswire
·
June 12, 2025
LONDON, June 12, 2025 (GLOBE NEWSWIRE) -- The UK is the best performer among G7 countries in addressing child sexual violence and is spearheading international efforts to end online sexual violence, but cuts in Official Development Assistance (ODA) are …
New trailer type gets strong underride guard
GlobeNewswire
·
June 12, 2025
ARLINGTON, Va., June 12, 2025 (GLOBE NEWSWIRE) -- A Stoughton chassis designed for container transport is the first of its kind to qualify for the Insurance Institute for Highway Safety’s TOUGHGUARD award for superior underride protection. Wisconsin-based …
Nusano Announces Breakthrough HALEU Program Expected to Produce Up to 350 Metric Tons of Fuel Annually for Advanced Nuclear Reactors
GlobeNewswire
·
June 12, 2025
Reservations available now, commercial production deliveries begin Q1 2027 Proprietary process with reduced environmental impacts Efficient domestic supply chain needed to support projected growth in energy demand from increased electrification and energy- …
Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD
GlobeNewswire
·
June 12, 2025
NEW YORK, June 11, 2025 (GLOBE NEWSWIRE) -- Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today provided an update on continued momentum with United States Food and Drug Administration (FDA) …